Rekürren castleman hastalığının tedavisinde radyoterapinin rolü

In this article, 29-year-old male patient with unicentric type, hyalen vascular Castleman’s disease with local recurrence after surgery and treated with radiotherapy is presented with management and related literature review.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Castleman's disease is benign and rare disease developing in lymph nodes.

📊

Key Findings & Data:It is characterized by B-cell hyperproliferation and B-cells produce interleukin-6.

💡

Conclusion & Impact:In this article, 29-year-old male patient with unicentric type, hyalen vascular Castleman’s disease with local recurrence after surgery and treated with radiotherapy is presented with management and related literature review.

🔬Design:Review & Systematic Survey

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Castleman's disease is benign and rare disease developing in lymph nodes. It is characterized by B-cell hyperproliferation and B-cells produce interleukin-6. This disease has two types; multicentric type often presents with fever, hepatomegaly, splenomegaly or lymphadenopathy, whereas unicentric type is diagnosed occasionally. Multicentric type is treated with combination chemotherapy regimens and unicentric type is treated with surgery and/or radiotherapy. In this article, 29-year-old male patient with unicentric type, hyalen vascular Castleman’s disease with local recurrence after surgery and treated with radiotherapy is presented with management and related literature review.

Özet

Rekürren Castleman hastalığının tedavisinde radyoterapinin rolü Castleman hastalığı lenf nodlarından gelişen benign ve nadiren görülen bir hastalıktır. B-lenfosit hiperproliferasyonu ile karakterizedir ve B-hücreleri IL-6 üretir. Bu hastalığın iki tipi vardır. Multisentrik tip sıklıkla ateş, hepatomegali, splenomegali ve Ienfadenopati ile prezente olur. Fakat unisentrik tip tesadüfen teşhis edilir. Multisentrik tip kombinasyon kemoterapi rejimleri ile ve unisentrik tip ise cerrahi ve/ veya radyoterapiyle tedavi edilir. Bu makalede 29 yaşında cerrahi sonrası nükseden ve radyoterapi ile tedavi edilen unisentrik, hyalen vasküler Castleman hastalıklı bir olgu tanı ve tedavi aşamaları değerlendirilerek ilgili literatür gözden geçirilmiştir.

🔖

Cite This Article

UYSAL, B., DINCOGLAN, F., SAĞER, Ö., SÜRENKÖK, S., KURT, B., OYSUL, K., GENÇ, O., BEYZADEOĞLU, M. M. (2014). Rekürren castleman hastalığının tedavisinde radyoterapinin rolü. Gülhane Tıp Dergisi, Cilt: 56 - Sayı: 1, 54–56. https://ajindex.com/articles/225299

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (13)

Sarrot—reynauld F. Castleman’s disease. Orphanet Encyclopedia 2001: 1-4. 2. 2. lsikdogan A, Ayyıldız O, Yakut M, Celik M. Multicentric plasma cell type castleman disease: case report. Int Hematol Oncol 2003; 13: 157-159. 3
Roodman D. Myeloma bone disease. Berlin: Springer, 2010: 51—52. 4
Root R. Clinical infectious diseases; practical approach. London: Oxford University Press, 1999: 505— 506. 5
Mauch P. Nonhodgkin lymphomas. In: Armitage J, Harris (eds). 2nd ed. Philadelphia: Lippincott Williams Wilkins 2009: 557—565. 6
Castleman B, Iverson L, Menendez VP. Localizedmediastinal lymph node hyperplasia resembling thymoma. Cancer 1956; 9: 822—830
Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, CoxJD. Treatmentofunicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001; 92: 670—676
Rodriguez Silva H, Buchaca Faxas E, Machado Puerto l, Perez Roman G, Perez Caballero D. Castleman’s disease: review of five cases. An Med lnterna 2005; 22: 24—27
Pekcici R, Alagöz F, Kartal R. Castleman’s disease with abdominal presentation: case report and review of the literature. Int Hematol Oncol 2002; 12: 201-205
Neuhof D, Debus J. Outcome and late complications of radiotherapy in patients with unicentric Castleman disease. Acta Oncol 2006; 45: 1126—1131
Rhee F, Stone K, Szmania S, Bariogie B, Singh Z. Castleman’s disease in the 21st century: an update on diagnosis, assesment, and therapy. Clin Adv Hematol Oncol 2010: 8; 486—498
Li Y, Liu P, Zhang Y, etal. Radiotherapy of unicentric mediastinal Castleman’s disease. Chin Cancer 2011; 30: 351—356
Vries l, Acht M, Demeyeree T, Lybeert M, Zoete JP, Nieuwenhuijzen G. Neoadjuvant radiotherapy of primary irresectable unicentric Castleman’s disease: case report and review of the literature. Radiat Oncol 2010; 5: 7
Farruggia P, Trizzino A, Scibetta N, etal. Castleman’s disease in the childhood: report of three cases and review of the literature. Ital Ped 2011; 37: 50.